Revenio Group Oyj

Director's Dealing • Jun 27, 2018

Disclosure 362981

Revenio Group Oyj - Managers' transactions

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Managers' transactions, July 27, 2017 at 14:20 Revenio Group Corporation: Managers' transactions Revenio Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Timo Hilden Position: Chief Executive Officer (X) Legal person Issuer: Revenio Group Oyj LEI: 743700I27E0FWSXLKK04 Notification type: INITIAL NOTIFICATION Reference number: 743700I27E0FWSXLKK04_20180627095558_2 ____________________________________________ Transaction date: 2018-06-26 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009010912 Nature of the transaction: EXERCISE OF A STOCK OPTION (X) Linked to stock option programme Transaction details (1): Volume: 1,000 Unit price: 17.7 EUR (2): Volume: 1,000 Unit price: 17.7 EUR Aggregated transactions (2): Volume: 2,000 Volume weighted average price: 17.7 EUR For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932 Distribution: Nasdaq Helsinki www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow- up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki. []